MX9702926A - L-eritrosilnucleosidos. - Google Patents

L-eritrosilnucleosidos.

Info

Publication number
MX9702926A
MX9702926A MX9702926A MX9702926A MX9702926A MX 9702926 A MX9702926 A MX 9702926A MX 9702926 A MX9702926 A MX 9702926A MX 9702926 A MX9702926 A MX 9702926A MX 9702926 A MX9702926 A MX 9702926A
Authority
MX
Mexico
Prior art keywords
erythrosyl
nucleosides
mammals
beta
alpha
Prior art date
Application number
MX9702926A
Other languages
English (en)
Other versions
MXPA97002926A (es
Inventor
Alexander L Weis
Charles T Goodhue
Tamas Bakos
Original Assignee
Genencor Int
Lipitek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genencor Int, Lipitek Inc filed Critical Genencor Int
Publication of MXPA97002926A publication Critical patent/MXPA97002926A/es
Publication of MX9702926A publication Critical patent/MX9702926A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Esta invencion se relaciona con alfa y beta-L-eritrosilnucleosidos, con procesos para su preparacion, con composiciones farmacéuticas que los contienen y métodos de utilizarlos para tratar varias enfermedades en mamíferos.
MX9702926A 1994-10-24 1995-10-24 L-eritrosilnucleosidos. MX9702926A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US328301 1994-10-24
US08/328,301 US5672594A (en) 1994-10-24 1994-10-24 L-erythrosyl nucleosides
PCT/US1995/013697 WO1996013498A2 (en) 1994-10-24 1995-10-24 L-erythrosyl nucleosides
US328,301 1995-10-24

Publications (2)

Publication Number Publication Date
MXPA97002926A MXPA97002926A (es) 1998-04-01
MX9702926A true MX9702926A (es) 1998-04-30

Family

ID=23280408

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9702926A MX9702926A (es) 1994-10-24 1995-10-24 L-eritrosilnucleosidos.

Country Status (5)

Country Link
US (1) US5672594A (es)
EP (1) EP0788495A2 (es)
JP (1) JPH10507771A (es)
MX (1) MX9702926A (es)
WO (1) WO1996013498A2 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE238328T1 (de) * 1996-10-16 2003-05-15 Ribapharm Inc Monozyklische l-nukleoside, analoga und ihre anwendungen
EP1254911A1 (en) * 1996-10-16 2002-11-06 ICN Pharmaceuticals, Inc. Monocyclic L-nucleosides, analogs and uses thereof
KR100412480B1 (ko) * 1996-10-16 2003-12-31 아이씨엔 파마슈티컬스, 인코포레이티드 푸린 ｌ-누클레오시드, 이의 유사체 및 이들의 용도
US6090602A (en) * 1998-02-18 2000-07-18 Promelas Research Corporation Levo-monosaccharide in a nucleoside analog for use as an anti-retroviral agent
WO1999045935A1 (en) * 1998-03-11 1999-09-16 Lipitek International, Inc. Novel nucleoside analogs and uses in treating disease
US6525191B1 (en) * 1999-05-11 2003-02-25 Kanda S. Ramasamy Conformationally constrained L-nucleosides
CN1267446C (zh) * 2001-01-22 2006-08-02 默克公司 作为依赖于rna的rna病毒聚合酶的抑制剂的核苷衍生物
US8481712B2 (en) 2001-01-22 2013-07-09 Merck Sharp & Dohme Corp. Nucleoside derivatives as inhibitors of RNA-dependent RNA viral polymerase
BR112013026345A2 (pt) 2011-04-13 2019-04-24 Merck Sharp & Dohe Corp. composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv
WO2012142093A2 (en) 2011-04-13 2012-10-18 Merck Sharp & Dohme Corp. 2'-cyano substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
EP2697242B1 (en) 2011-04-13 2018-10-03 Merck Sharp & Dohme Corp. 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
US9416154B2 (en) 2011-07-13 2016-08-16 Merck Sharp & Dohme Corp. 5′-substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases
WO2013009737A1 (en) 2011-07-13 2013-01-17 Merck Sharp & Dohme Corp. 5'-substituted nucleoside analogs and methods of use thereof for the treatment of viral diseases

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2648239C3 (de) * 1975-10-24 1981-11-12 Rikagaku Kenkyusho, Wako, Saitama Di-(trialkylstannyl)-pyrimidinderivate, Verfahren zu ihrer Herstellung und Verfahren zu ihrer Weiterverarbeitung zu nucleosidartigen Pyrimidinderivaten
DD140254A1 (de) * 1978-12-04 1980-02-20 Dieter Baerwolff Verfahren zur herstellung von 4-substituierten pyrimidin-nucleosiden
DD228810A1 (de) * 1984-10-18 1985-10-23 Adw Ddr Verfahren zur herstellung von cycloalkylether-derivaten des 6- fluorthymins
JPS61145167A (ja) * 1984-12-18 1986-07-02 Sagami Chem Res Center １，３−二置換−５−フルオロ−６−クロロウラシル誘導体及び抗腫瘍剤
KR910009957B1 (ko) * 1989-12-29 1991-12-07 한국과학기술원 2-푸릴피리미딘 유도체의 제조방법

Also Published As

Publication number Publication date
JPH10507771A (ja) 1998-07-28
EP0788495A2 (en) 1997-08-13
WO1996013498A2 (en) 1996-05-09
WO1996013498A3 (en) 1996-10-03
US5672594A (en) 1997-09-30

Similar Documents

Publication Publication Date Title
MX9702932A (es) L-ribofuranosilnucleosidos.
IL125282A (en) Substituted imidazole compounds, process for their preparation, pharmaceutical compositions containing them and use thereof in the preparation of medicaments for treating cytokine mediated diseases
ATE179330T1 (de) Verbesserte alpha-interferon-zusammensetzung und verfahren zu ihrer herstellung aus leukocyten des menschlichen peripheren blute
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
MX9705296A (es) Compuestos novedosos de imidazol 1,4,5-susbtituidos y el uso de los mismos para preparar composiciones para uso en terapia.
BG101118A (en) Therapeutical compounds
MX9704030A (es) 1,1-dioxidos de 2-heterocicliloxi y tiometil-1,2,5-tiadiazolidin-3-ona y composiciones y metodo de uso de los mismos.
FR2707882B1 (fr) Nouveaux kits thérapeutiques anti-médiateurs protéiques, procédé de préparation et compositions pharmaceutiques les renfermant.
MX9702926A (es) L-eritrosilnucleosidos.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
DE69911401D1 (en) Immunoregulator
PL316656A1 (en) Free halophantrin base for use in treating marsh-fever and compositions containing same
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
SG52537A1 (en) Methods and compositions for the treatment of cell proliferation disorders
FR2651435B1 (es)
MX9702927A (es) L-piranosilnucleosidos.
MX9800049A (es) Antraquinonas mono- y disulfo-substituidas y su uso para el tratamiento de trastornos de la matriz del hueso.
PL318130A1 (en) Terpenod derivatives (of sarcodictyine)as antineoplastic agents
ES8301244A1 (es) Procedimiento para la obtencion de derivados de sisomicina.
GR3020575T3 (en) New 2-amino-5-cyano-1,4-dihydropyridines, process for their preparation and use in pharmaceutical compositions
ES2016464A6 (es) Procedimiento para preparar derivados de 2', 5' -oligoadenilato.
MD960168A (ro) Metodă şi compuşi pentru tratamentul infecţiilor virale
ES8607217A1 (es) Un procedimiento para la preparacion de (r)-4-amino-n-(1-fe-niletil)benzamida,(s)-4-amino-n-(1-feniletil)benzamida,o unasal de las mismas
IL88726A0 (en) Dihydrothienobenzodiazepinone derivatives,pharmaceutical compositions containing the same and processes for the preparation thereof
UA37217C2 (uk) Аналоги 15-дезоксиспергуаліну, спосіб їх одержання, фармацевтична композиція та проміжні сполуки

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees